MerusCase - Technology for Attorneys No more bulky files lying around, and no more having to spend 15 minutes looking for a file: everything we need is easily accessible in Merus We have used other case management systems, but Merus is by far the best It is the most advanced case management system, and it’s very user friendly
Pipeline - Merus Merus has exclusively licensed Betta Pharmaceuticals Co Ltd to develop and potentially commercialize MCLA-129 in China, while Merus retains full rights ex-China
News Releases - Merus SAN DIEGO and UTRECHT, The Netherlands and CAMBRIDGE, Mass , Nov 17, 2025 PRNewswire -- Merus N V (Nasdaq: MRUS) ("Merus"), an oncology company developing innovative, full-length multispecific antibodies and antibody drug conjugates (Biclonics ® , Triclonics ® and ADClonics ® ), and Halozyme
About Us - Merus At Merus, we are clinically advancing leading-edge, targeted treatments to address the unmet needs of patients with various types of cancer
Login - MerusCase Forgot Password? Don't have an account? Request a Demo
Genmab Strikes $8 Billion Deal To Acquire Cancer-Focused Merus Genmab (GMAB), on Monday, announced its plan to buy cancer-focused biotech company Merus (MRUS) for about $8 billion The news sent Merus stock into the stratosphere Merus is working on a
Genmab pays $8B to buy Merus and phase 3-stage bispecific Genmab is continuing to build up its pipeline of wholly owned late-stage cancer assets, this time paying $8 billion for Netherlands-based Merus and its bispecific antibody